ERAS
Erasca, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.77
−3.72%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$15.41
From 52W high−34.27%
Volume8.50M
Market cap$5.17B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$15.41
From 52W high
−34.27%
Volume
8.50M
Market cap
$5.17B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−17.4x
P/E (TTM)
—
RSI (14)
30.8
MomentumView details →
1D Return
−3.72%
YTD Return
+291.06%
SummaryUpdated Jun 1, 2026
Erasca, Inc. (NASDAQ:ERAS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California. The company went public in July 2021 and focuses on developing targeted cancer therapies for patients with RAS/MAPK pathway-driven cancers. As a clinical-stage company, Erasca has no approved products or revenue yet, but maintains a robust pipeline of investigational drugs targeting various cancer types including lung cancer, colorectal cancer, acute myeloid leukemia, and brain tumors.
Similar companies
Latest newsMore news →
Grabar Law Office announced it is investigating whether certain officers and directors of Erasca, Inc. breached their fiduciary duties owed to the company and its shareholders.5d agoErasca, Inc. announced that updated monotherapy clinical data from the Phase 1 AURORAS-1 trial of ERAS-0015 and nonclinical combination data of ERAS-0015 and ERAS-4001 will be presented at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 18-20, 2026.10d agoBernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Erasca, Inc.25d ago